AF
ZVRA icon

Allworth Financial’s Zevra Therapeutics ZVRA Stock Holding History

Allworth Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.53K Buy
595
+565
+1,883% +$6.28K ﹤0.01% 3819
2026
Q1 		$280 Sell
30
-6
-17% -$54 ﹤0.01% 4863
2025
Q4 		$323 Sell
36
-19
-35% -$180 ﹤0.01% 4622
2025
Q3 		$524 Buy
55
+30
+120% +$301 ﹤0.01% 4424
2025
Q2 		$221 Buy
+25
New +$203 ﹤0.01% 4304

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allworth Financial's ZVRA Position: Q2 2026 in Review

Allworth Financial increased its Zevra Therapeutics (ZVRA) stake by 1,883% in Q2 2026, buying an estimated $6.28K and bringing the position to 595 shares worth $8.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3819.

Allworth Financial first reported a position in ZVRA in Q2 2025 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Allworth Financial held 595 shares of Zevra Therapeutics worth $8.53K as of Q2 2026.
  • Allworth Financial bought 565 Zevra Therapeutics shares in Q2 2026, an estimated $6.28K.
  • Zevra Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3819 holding.
  • Allworth Financial first reported a position in Zevra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.